CellProtect Nordic Pharmaceuticals has developed a unique manufacturing technology , and in collaboration with Karolinska Centre for Cell Therapy, Vecura , this technology has been established and validated. The method is proprietary to the Company.

Scientific publications

Anti-myeloma activity of endogenous and adoptively transferred activated natural killer cells in experimental Multiple Myeloma model (Alici 2007_Exp Hematology)

Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components (Alici 2008_Blood)

Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor (Tolga et al. 2010; Cytotherapy)